Therapeutic Radiopharmaceuticals


Combined with:

Fluorouracil

Indications and Reactions:

Role Indications Reactions
Secondary
Rectal Cancer 27.4%
Oesophageal Carcinoma 11.2%
Hodgkin's Disease 10.6%
Breast Cancer 9.2%
Hypertension 7.3%
Head And Neck Cancer 4.3%
Atrial Fibrillation 3.4%
Rheumatoid Arthritis 3.2%
Nasopharyngeal Cancer 2.8%
Mantle Cell Lymphoma 2.6%
Malnutrition 2.3%
Pain 2.3%
Asthma 2.1%
Prophylaxis 2.1%
Non-small Cell Lung Cancer Stage Iii 2.0%
Langerhans' Cell Histiocytosis 1.5%
Acute Lymphocytic Leukaemia Recurrent 1.4%
Nausea 1.4%
Squamous Cell Carcinoma Of Head And Neck 1.4%
Cervix Carcinoma 1.2%
Diarrhoea 8.4%
Neutropenia 8.4%
Toxicity To Various Agents 7.1%
Stem Cell Transplant 6.5%
Acute Myeloid Leukaemia 5.8%
Pulmonary Embolism 5.8%
Pyrexia 5.8%
Vomiting 5.8%
Leukopenia 5.2%
Pneumonitis 5.2%
Death 4.5%
Dehydration 4.5%
Wound Infection 4.5%
Myocardial Infarction 3.9%
Urinary Tract Infection 3.9%
Failure To Anastomose 3.2%
Pharyngeal Haemorrhage 3.2%
Urinary Retention 3.2%
Anaemia 2.6%
Interstitial Lung Disease 2.6%
Concomitant
Adenocarcinoma Pancreas 19.3%
Product Used For Unknown Indication 17.9%
Rectal Cancer 10.3%
Breast Cancer 5.6%
Pancreatic Carcinoma 5.6%
Non-small Cell Lung Cancer 4.9%
Neoplasm 4.5%
Pancreatic Carcinoma Non-resectable 4.5%
Prophylaxis 4.3%
Lung Squamous Cell Carcinoma Stage Iv 2.7%
Premedication 2.7%
Diffuse Large B-cell Lymphoma 2.2%
Multiple Myeloma 2.2%
Prostate Cancer 2.2%
Hypopharyngeal Cancer 2.0%
Rectal Adenocarcinoma 2.0%
Bone Metastases 1.8%
Cancer Of Prostate 1.8%
Metastases To Bone 1.8%
Post Procedural Diarrhoea 1.8%
Gastrointestinal Toxicity 12.8%
White Blood Cell Count Decreased 11.3%
Thrombocytopenia 9.0%
Melaena 8.3%
Vomiting 6.0%
Gastrointestinal Disorder 5.3%
Myocardial Infarction 5.3%
Cholangitis 4.5%
Pneumonia 4.5%
Urticaria 4.5%
Device Occlusion 3.8%
Nausea 3.0%
Platelet Count Decreased 3.0%
Portal Vein Thrombosis 3.0%
Pyrexia 3.0%
Radiation Pneumonitis 3.0%
Right Ventricular Failure 3.0%
Death 2.3%
Gastric Haemorrhage 2.3%
Myelodysplastic Syndrome 2.3%

Drug Data